uniQure (NASDAQ:QURE) Reaches New 52-Week High – Should You Buy?

uniQure (NASDAQ:QURE) reached a new 52-week high during trading on Tuesday . The stock traded as high as $19.00 and last traded at $18.88, with a volume of 109599 shares changing hands. The stock had previously closed at $18.08.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on QURE shares. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday, December 11th. Stifel Nicolaus lifted their price objective on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Royal Bank of Canada lifted their price target on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Finally, The Goldman Sachs Group increased their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.88.

uniQure Price Performance

The firm has a market capitalization of $775.99 million, a PE ratio of -3.21 and a beta of 0.41. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The business’s 50 day moving average is $11.03 and its two-hundred day moving average is $7.90.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, research analysts anticipate that uniQure will post -3.82 EPS for the current year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently made changes to their positions in QURE. Franklin Resources Inc. purchased a new stake in uniQure during the third quarter valued at about $7,360,000. Geode Capital Management LLC grew its position in shares of uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 6,362 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of uniQure in the 3rd quarter worth about $283,000. Quarry LP purchased a new position in uniQure during the 3rd quarter valued at about $58,000. Finally, RTW Investments LP bought a new stake in uniQure during the third quarter worth about $49,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.